Navigation Links
MiMedx Files Its Initial Investigational New Drug Application
Date:7/23/2014

sue technologies processed from human amniotic membrane that is derived from donated placentas.  Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 250,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to the effect of the filing of the IND application and the Company's ability to transition its micronized products to licensed biologics or pursue BLAs for future products.  These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the IND application will not be granted, that the associated clinical trials will not be successful, that the Company will not apply for or be granted one or more BLAs, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2013.  By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MiMedx Group to Present at the Stifel Nicolaus 2012 Healthcare Conference
2. MiMedx Group to Present at the 6th Annual OneMedForum
3. MiMedx Announces 2012 Results
4. MiMedx Group, Inc. Announces Release Date for 2013 Second Quarter Results
5. MiMedx Addresses FDA Untitled Letter And Reiterates 2013 And 2014 Guidance
6. MiMedx Announces Conference Call To Discuss FDA "Untitled Letter" And Reiterate Guidance
7. MiMedx to meet with FDA in Mid-October
8. Seven Poster Abstracts Highlight MiMedx Allografts at the 10th Annual Desert Foot Conference
9. MiMedx Announces Next Steps After Discussions With The FDA
10. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
11. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 A lot of discussion in ... for treating  certain illnesses, injuries, or conditions. As medical science ... treatment methods with ones that they consider to be more ... is not one textbook method of treatment that stands out ...
(Date:1/23/2015)... Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... therapies for operable and inoperable solid tumor cancers, announced today ... 7 th Annual Phacilitate Immunotherapy Forum in ... Phacilitate will take place on January 26 at 10:30 a.m. ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... Feb. 10 Amira Pharmaceuticals, Inc. announced today ... Flavia V. Castelino , M.D. of Massachusetts General Hospital, ... which demonstrates that the bioactive lipid lysophosphatidic acid (LPA), through ... fibrogenesis in the bleomycin mouse model of scleroderma.  Data will ...
... OXFORD, England , February 10 ... the needle-free administration of solid,dose therapeutics and vaccines, today ... ( $4.3 million ) investment round. The,fundraising was ... including Hygea VCT and Oxford Technology VCTs. The company ...
Cached Medicine Technology:Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma 2Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round 2Glide Pharma Completes Oversubscribed GBP2.7 Million ($4.3 Million) Investment Round 3
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
(Date:1/22/2015)... 22, 2015 Yesterday, Senator Holly ... and Kristin Olsen (R-Modesto) were honored by the ... advancing biotechnology, biomedical science, medical device and pharmaceutical ... received the “2014 Life Sciences Champion” award from ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
(Date:1/22/2015)... January 22, 2015 Payday lending practices ... communities and cause financial distress to the states that ... at Howard University’s Center on Race and Wealth. , ... economic activity, payday loans at the same time substantially ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2
... doctors say sunitinib,s benefits outweigh its risks , , WEDNESDAY, ... sunitinib (Sutent) can cause high blood pressure in patients ... echoes the results of a study published last month ... risk of heart failure among patients with stomach cancer. ...
... Mich. One in four Americans in the hospital right ... get a urinary tract infection from that catheter. All of ... , And with every new case, UTIs will retain ... percent of infections related to hospitalization. , But despite ...
... University of California, San Francisco are reporting significant results ... the safe removal of tumors near language pathways in ... reduces the amount of time a patient must be ... study provides new data that refines scientists understanding of ...
... a non-invasive way to determine the existence and extent ... of pharmacologic strategies to combat the condition. These findings ... published by John Wiley & Sons on behalf of ... (AASLD). The article is also available online at Wiley ...
... most common cause of disability in the United States. ... continues to age, the toll of this disease will escalate. ... burden and its impact on our nations health care and ... by any form of arthritisis critical. , The National Arthritis ...
... of chemicals in red wine grapes may significantly reduce ... a study published recently in the Journal of Agricultural ... present in large amounts in fermented seeds and skins ... ability of bacteria to contribute to tooth decay. Beyond ...
Cached Medicine News:Health News:New Cancer Drug Boosts Blood Pressure 2Health News:New Cancer Drug Boosts Blood Pressure 3Health News:Catheter chaos: Hospitals lag in preventing common infection 2Health News:Catheter chaos: Hospitals lag in preventing common infection 3Health News:Catheter chaos: Hospitals lag in preventing common infection 4Health News:Language centers revealed, brain surgery refined with new mapping 2Health News:Language centers revealed, brain surgery refined with new mapping 3Health News:MRI techniques evolving towards better assessment of liver fibrosis 2Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 2Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 3Health News:Winemaking waste proves effective against disease-causing bacteria in early studies 2Health News:Winemaking waste proves effective against disease-causing bacteria in early studies 3Health News:Winemaking waste proves effective against disease-causing bacteria in early studies 4
... enzyme immunoassays, designed to meet the working ... allows the user to run set assays ... floating manifold on this strip washer adjusts ... a time. Reliable, compact, and self-contained, offers ...
... miniGene LW is a new plate washing system ... and 384 channel microplates with flat, V-shaped or ... 8 or 16 channel nozzle heads. Simple LCD ... An optional plate stacker is available for the ...
... to 8000 L/day of Type III Laboratory-grade ... to produce up to 8000 L/day of ... feedwater., One Complete Purification and Control Unit, ... centralized system, providing total control of all ...
... Up to 8000 L/day of Type III ... designed to produce up to 8000 L/day ... tap feedwater., One Complete Purification and Control ... a centralized system, providing total control of ...
Medicine Products: